TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A University of Florida analysis of health records found that glucosamine use was associated with a 25% higher likelihood that mild cognitive impairment would progress to dementia. The retrospective findings do not establish that glucosamine causes progression, and the researchers say a human clinical trial is needed.
People with mild cognitive impairment (MCI) who reported taking glucosamine were more likely to progress to dementia in a University of Florida analysis of health records, researchers reported in a study published in Nature Metabolism. The retrospective study found an association, not proof that the joint supplement caused cognitive decline, and its authors say the finding needs testing in a human clinical trial.
The research team used artificial intelligence to analyze deidentified UF Health records from 2012 to 2024. The analysis included patients diagnosed with Alzheimer’s disease and related dementias, as well as patients with MCI. In each group, about 8% reported glucosamine use: 1,896 people in the dementia group and 2,750 in the MCI group.
After accounting for age, sex and demographics, the researchers found glucosamine use was associated with a 25% higher likelihood of MCI progressing to dementia. Among people already diagnosed with Alzheimer’s disease or a related dementia, use was associated with a 25% higher mortality risk during the study’s defined period. The researchers did not observe that mortality association in the MCI group. The supplied report does not specify the mortality follow-up window.
The health-record analysis was accompanied by experiments involving human brain tissue and mouse models. The team investigated a metabolic pathway involved in building sugar structures and attaching them to proteins. Researchers reported signs of excessive activity in this pathway in Alzheimer’s disease and proposed that it could help explain the observed association. These experiments offer a possible biological explanation; they do not establish that supplement use causes dementia progression in people.
A Common Supplement, A Clinical Question
Glucosamine is widely sold over the counter and is often used by older adults for joint discomfort. The findings matter because they raise a question about a supplement that people may take without discussing it with a clinician, including people who already have memory or thinking problems. The study does not show that users should stop taking it, or that nonusers are protected from dementia.
The results also broaden the research question beyond the brain features most commonly associated with Alzheimer’s: amyloid plaques and tau tangles. The UF team’s proposed metabolic pathway could point to another process involved in disease progression. Senior author Ramon Sun said altered metabolism may contribute to Alzheimer’s progression and could complement research focused on plaques and tangles. That is a research direction, not an established treatment strategy.
For clinicians and patients, the immediate relevance is the need to weigh an uncertain observational signal carefully. The study cannot separate the effect of glucosamine from other differences between people who choose to take it and those who do not. A controlled trial would be needed to test whether the supplement itself changes outcomes.
How Researchers Traced The Link
The study began with records of patients diagnosed with MCI or Alzheimer’s disease and related dementias. MCI refers to measurable difficulty with memory or thinking beyond what is expected with normal aging; it does not necessarily substantially disrupt daily life. Some people with MCI later develop dementia, while the diagnosis itself does not mean progression is certain.
To investigate a possible biological connection, the researchers examined metabolic changes using spatial technology developed in Sun’s laboratory. The report says the method can map thousands of molecules in tissue and help identify pathways that may otherwise be difficult to detect. The team then focused on glucosamine, a naturally occurring sugar-related molecule that can cross the blood-brain barrier and enter biochemical pathways involved in attaching sugar structures to proteins.
Commercial supplements can be made from sources including shellfish shells or corn. The researchers suggested that glucosamine’s effects may depend on the biological environment, so a healthy brain and a brain affected by Alzheimer’s might respond differently. The study’s record analysis covered 2012 through 2024; its results were reported in September 2026.
“The electronic health record data are very provocative.”
— Matt Gentry, chair of the University of Florida Department of Biochemistry and Molecular Biology and study co-author
Cause, Risk And Dose Remain Unclear
The retrospective records show an association, not causation. People taking glucosamine may differ in other ways from people who do not, and the analysis cannot establish whether those differences help explain the results. The report says the researchers adjusted for age, sex and demographics, but that adjustment cannot rule out all potential confounding factors.
The available findings do not establish whether glucosamine itself contributed to MCI progression, whether the association applies beyond the patients in the records, or how factors such as dose and duration relate to outcomes. The report also does not provide enough detail to assess the mouse experiments’ results or the specific human brain tissue findings. The observed mortality association was limited to the group already diagnosed with dementia; it was not seen in the MCI group.
Most of all, it remains unknown whether glucosamine use changes dementia outcomes in a controlled human study. The researchers describe the results as preliminary and say they need to be tested in a human clinical trial.
Clinical Trials Must Test The Signal
The next step identified by the researchers is a human clinical trial to test whether glucosamine affects cognitive or dementia outcomes. A trial could examine supplement use under controlled conditions and address questions that a health-record study cannot settle, including whether the association reflects a direct effect. The supplied report does not give a trial start date, design or planned enrollment.
Until such evidence is available, the study is a preliminary signal for further investigation. Anyone concerned about glucosamine use alongside a cognitive diagnosis can discuss their supplements and health circumstances with a qualified health professional. The study alone does not establish a clinical recommendation to start, stop or change a supplement.
Key Questions
Did the study prove glucosamine causes dementia?
No. The researchers found an association in retrospective health records. That design cannot establish that glucosamine caused progression from MCI to dementia.
What association did the researchers report?
After accounting for age, sex and demographics, reported glucosamine use was associated with a 25% higher likelihood that MCI would progress to dementia. The study also found an association with a 25% higher mortality risk among people already diagnosed with Alzheimer’s disease or a related dementia.
Should people stop taking glucosamine?
The study does not establish that people should stop taking the supplement. Anyone with concerns about supplements and a cognitive diagnosis can discuss their situation with a qualified health professional.
What research is needed next?
The researchers say the findings need testing in a human clinical trial. The report does not provide a timeline or details for such a trial.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
